A dose-finding study of sufentanil sublingual microtablets for the management of postoperative bunionectomy pain
| Autor: | Neil Singla, Mark A. Evashenk, Derek D. Muse, Pamela P. Palmer |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Sufentanil Nausea Administration Sublingual Critical Care and Intensive Care Medicine Placebo Double-Blind Method Acute care medicine Clinical endpoint Humans Hallux Valgus Adverse effect Aged Pain Postoperative business.industry Middle Aged Surgery Analgesics Opioid Anesthesia Ambulatory Vomiting Female medicine.symptom business Tablets medicine.drug |
| Zdroj: | Journal of Trauma and Acute Care Surgery. 77:S198-S203 |
| ISSN: | 2163-0755 |
| DOI: | 10.1097/ta.0000000000000373 |
| Popis: | BACKGROUND: Sufentanil sublingual microtablets (SSMs) at a dose of 15 Hg per tablet have been studied for postoperative patient-controlled analgesia with a 20-minute lockout via a bedside handheld system over 2 days to 3 days of use. For more short-term (G24 hours) management of acute moderate-to-severe pain, such as in the ambulatory surgical setting, a single, higher-strength SSM dose administered via a health care provider would be of benefit as it would require less frequent administration and avoid the setup of a drug delivery system. METHODS: This study was a two-center, randomized, double-blind, placebo-controlled trial for 12 hours in patients 18 years to 80 years of age who were undergoing bunionectomy alone or with hammertoe repair. Patients were randomly assigned at a 2:2:1 ratio to treatment with SSM 20 Hg, SSM 30 Hg, or placebo. The primary endpoint was time-weighted summed pain intensity difference to baseline over 12 hours (SPID12). Patients had to have a pain intensity score of 4 or higher just before initial microtablet dosing. Additional doses were administered when requested by the patient, with a minimum redosing interval of 1 hour. RESULTS: One hundred patients were randomized and received study drug. The SSM 30 Hg was superior in the treatment of postbunionectomy surgical pain compared with placebo as demonstrated by the SPID12 score (6.53 vs. j7.12, respectively; p =0 .003) as well as all other secondary efficacy end points. The SSM 20-Hg dosage strength was not superior to placebo for primary or secondary efficacy measures. Adverse events were similar among the three groups with the exception of nausea, vomiting, and somnolence, which demonstrated a dose-dependent increase in occurrence. CONCLUSION: The SSM 30 Hg may be an effective, noninvasive alternative to health care providerYadministered intravenous, intramuscular, or oral opioids for the management of moderate-to-severe acute pain. (J Trauma Acute Care Surg. 2014;77: S198YS203. Copyright * 2014 by Lippincott Williams & Wilkins) LEVEL OF EVIDENCE: Therapeutic study, level I. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|